Major Setback for Pfizer: Obesity Pill Development Halted Due to Liver Injury Concerns
2 months ago
In a significant development within the pharmaceutical sector, Pfizer Inc. has announced the abandonment of its obesity treatment pill, a decision driven by alarming reports of liver injuries associated with the medication. This setback marks a considerable shift in the company's strategy to target the growing obesity epidemic, which has seen a dramatic rise in global prevalence in recent years.
Continue reading
Medicare's Future Spending: Obesity Drugs Projected to Cost $35 Billion by 2034
8 months ago
In a significant healthcare development, it has been projected that Medicare will incur expenses exceeding $35 billion for obesity drugs over the next decade. This forecast stems from the growing adoption of weight-loss medications, which have been increasingly recognized for their efficacy in combating obesity.
Continue reading